Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZE: Mitapivat in Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
2024-512745-16-00Phase 3Authorised
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Thalassaemia comparing Mitapivat arm with Placebo arm (2 arms). Primary endpoint: Hemoglobin response from Week 12 through Week 24. Planned start Jul 2024; status: authorised.
02
Drugs
mitapivat
03
Conditions
Thalassaemia
Beyond the preview
Go deeper on 2024-512745-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512745-16-00.